Active, not recruitingPhase 1NCT04640779
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Studying Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Jonas Paludo, MDMayo Clinic in Rochester
- Intervention
- Choline Salicylate(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (1)
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04640779 on ClinicalTrials.govOther trials for Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07374068Prognostic Model of Elderly Hodgkin Lymphoma in ChinaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNCT07356882European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin LymphomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT06848569Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II StudySun Yat-sen University
- RECRUITINGPHASE2, PHASE3NCT06563245Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT AssessmentChildren's Cancer Group, China
- RECRUITINGPHASE2NCT04838652Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaUniversity of Cologne
- RECRUITINGPHASE2NCT05900765A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaSun Yat-sen University
- RECRUITINGNCT06822855Changing Paragidms In The Prognostic Assessment Of Hodgkin LymphomaAzienda USL Reggio Emilia - IRCCS
- ACTIVE NOT RECRUITINGPHASE2NCT04268706Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)Tessa Therapeutics